Phenotypic screening in cancer drug discovery — past, present and future
The DOI matches its Crossref record; 181 of the 182 references it cites were found in a registry or an index.
Abstract
There has been a resurgence of interest in the use of phenotypic screens in drug discovery as an alternative to target-focused approaches. Given that oncology is currently the most active therapeutic area, and also one in which target-focused approaches have been particularly prominent in the past two decades, we investigated the contribution of phenotypic assays to oncology drug discovery by analysing the origins of all new small-molecule cancer drugs approved by the US Food and Drug Administration (FDA) over the past 15 years and those currently in clinical development. Although the majority of these drugs originated from target-based discovery, we identified a significant number whose discovery depended on phenotypic screening approaches. We postulate that the contribution of phenotypic screening to cancer drug discovery has been hampered by a reliance on 'classical' nonspecific drug effects such as cytotoxicity and mitotic arrest, exacerbated by a paucity of mechanistically defined cellular models for therapeutically translatable cancer phenotypes. However, technical and biological advances that enable such mechanistically informed phenotypic models have the potential to empower phenotypic drug discovery in oncology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Phenotypic screening is a strategy that analyzes biology-associated (phenotypic) effects in given models such as animals, cells, or organisms to help identify the targets of candidate drugs.25,50”
From Drug repurposing for cancer therapy (2024) · cites this paper as [25]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Cited by
Natural products as sources of new drugs from 1981 to 2014
Newman, D. J., & Cragg, G. M. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b01055 · Cited by 5,858
Natural product discovery: past, present, and future
Katz, L., & Baltz, R. H. (2016) · Journal of Industrial Microbiology and Biotechnology · doi:10.1007/s10295-015-1723-5 · Cited by 1,144
“Both target-based and phenotypic screening are too vast to be described comprehensively here, but are covered in a number of reviews [74, 81, 102, 118].”
BackgroundBray, M.-A., Singh, S., Han, H., Davis, C. T., Borgeson, B., Hartland, C., Kost-Alimova, M., Gustafsdottir, S. M., Gibson, C. C., & Carpenter, A. E. (2016) · Nature Protocols · doi:10.1038/nprot.2016.105 · Cited by 1,090
Opportunities and challenges in phenotypic drug discovery: an industry perspective
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.111 · Cited by 939
Self-citationMetallodrugs are unique: opportunities and challenges of discovery and development
Anthony, E. J., Bolitho, E. M., Bridgewater, H. E., Carter, O. W. L., Donnelly, J. M., Imberti, C., Lant, E. C., Lermyte, F., Needham, R. J., Palau, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc04082g · Cited by 692
Franken, H., Mathieson, T., Childs, D., Sweetman, G. M. A., Werner, T., Tögel, I., Doce, C., Gade, S., Bantscheff, M., Drewes, G., et al. (2015) · Nature Protocols · doi:10.1038/nprot.2015.101 · Cited by 659
Screening out irrelevant cell-based models of disease
Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L. S., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.175 · Cited by 525
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
“However, a major challenge in cancer drug discovery is to maximize the probability that drugs discovered by either biochemical or phenotypic methods will lead to clinical efficacy and improved disease management.(8,30,44,45) It should be realized that cell-based models frequently do not accurately represent the true i…”
BackgroundMethodDrug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
“…experimental approach considers tools such as induced pluripotent stem cell models and function-fi rst phenotypic screenings (or reverse chemical biology), 25,26 while computational methods use target-centric, knowledge-driven, signature-aligned, pathway-focused, and mechanism-speci fi c strategies.”
MethodSelective small-molecule inhibition of an RNA structural element
Howe, J. A., Wang, H., Fischmann, T. O., Balibar, C. J., Xiao, L., Galgoci, A. M., Malinverni, J. C., Mayhood, T., Villafania, A., Nahvi, A., et al. (2015) · Nature · doi:10.1038/nature15542 · Cited by 407
Bender, A., & Cortés-Ciriano, I. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2020.12.009 · Cited by 405
Phenotypic drug discovery: recent successes, lessons learned and new directions
Vincent, F., Nueda, A., Lee, J., Schenone, M., Prunotto, M., & Mercola, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00472-w · Cited by 348
Autonomous Discovery in the Chemical Sciences Part I: Progress
Coley, C. W., Eyke, N. S., & Jensen, K. F. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201909987 · Cited by 317
A systematic analysis of FDA-approved anticancer drugs
Sun, J., Wei, Q., Zhou, Y., Wang, J., Liu, Q., & Xu, H. (2017) · BMC Systems Biology · doi:10.1186/s12918-017-0464-7 · Cited by 322
“We further checked the multiple sources such as the MyCancerGenome [22], DrugBank, and the several publications [4, 23] to obtain the drug targets.”
MethodRational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms
Zhou, J., Jiang, X., He, S., Jiang, H., Feng, F., Liu, W., Qu, W., & Sun, H. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00017 · Cited by 281
Martinez Molina, D., & Nordlund, P. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103715 · Cited by 306
Drug repurposing in oncology—patient and health systems opportunities
Bertolini, F., Sukhatme, V. P., & Bouche, G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.169 · Cited by 294
A Guide to In Silico Drug Design
Chang, Y., Hawkins, B. A., Du, J. J., Groundwater, P. W., Hibbs, D. E., & Lai, F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010049 · Cited by 250
“notype screening [8,9], and bioinformatics (e.”
MethodMachine Learning in Genomic Medicine: A Review of Computational Problems and Data Sets
Leung, M. K. K., Delong, A., Alipanahi, B., & Frey, B. J. (2016) · Proceedings of the IEEE · doi:10.1109/jproc.2015.2494198 · Cited by 275
“Insight into disease mechanisms is important for the purpose of developing targeted therapies, but can also provide complementary information for phenotypic screens, which traditionally identifies chemicals with desired biological effects without knowledge of the precise targets [28].”
BackgroundBioinformatics and Drug Discovery
Xia, X. (2017) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026617666161116143440 · Cited by 252
“This new conceptual framework of cancer biology contributed to the progress of mechanismbased anti-cancer drug development in the following years [10-12].”
BackgroundChemical probes and drug leads from advances in synthetic planning and methodology
Gerry, C. J., & Schreiber, S. L. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.53 · Cited by 230
Application of Cancer Organoid Model for Drug Screening and Personalized Therapy
Kondo, J., & Inoue, M. (2019) · Cells · doi:10.3390/cells8050470 · Cited by 224
Nacev, B. A., Jones, K. B., Intlekofer, A. M., Yu, J. S. E., Allis, C. D., Tap, W. D., Ladanyi, M., & Nielsen, T. O. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0288-4 · Cited by 209
Dissecting fibrosis: therapeutic insights from the small-molecule toolbox
Nanthakumar, C. B., Hatley, R. J. D., Lemma, S., Gauldie, J., Marshall, R. P., & Macdonald, S. J. F. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4592 · Cited by 208
High-Content Monitoring of Drug Effects in a 3D Spheroid Model
Mittler, F., Obeïd, P., Rulina, A. V., Haguet, V., Gidrol, X., & Balakirev, M. Y. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00293 · Cited by 194
Systematic Targeting of Protein–Protein Interactions
Modell, A. E., Blosser, S. L., & Arora, P. S. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.05.008 · Cited by 184
“Similarly, the anticancer drug lenalidomide, which has been approved by the US FDA, was discovered from a phenotypic screen, but its target, the E3 ligase protein cereblon, was not elucidated until years after its approval in 2012 [3,7].”
InfluentialBoyd, N. K., Teng, C., & Frei, C. R. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.684515 · Cited by 197
Machine learning and image-based profiling in drug discovery
Scheeder, C., Heigwer, F., & Boutros, M. (2018) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2018.05.004 · Cited by 169
Analysis of Racial/Ethnic Representation in Select Basic and Applied Cancer Research Studies
Guerrero, S., López-Cortés, A., Indacochea, A., García-Cárdenas, J. M., Zambrano, A. K., Cabrera-Andrade, A., Guevara-Ramírez, P., González, D. A., Leone, P. E., & Paz-y-Miño, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-32264-x · Cited by 163
Mateus, A., Määttä, T. A., & Savitski, M. M. (2016) · Proteome Science · doi:10.1186/s12953-017-0122-4 · Cited by 177
Recent advances in identifying protein targets in drug discovery
Ha, J., Park, H., Park, J., & Park, S. B. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.12.001 · Cited by 176
Major achievements of evidence-based traditional Chinese medicine in treating major diseases
Chao, J., Dai, Y., Verpoorte, R., Lam, W., Cheng, Y.-C., Pao, L.-H., Zhang, W., & Chen, S. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.06.123 · Cited by 158
Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy
Wen, S., Wang, G., Zhang, Y., Bu, F., Zhang, S., Miller, D. D., Li, W., Ouyang, L., & Wang, Y. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00100 · Cited by 155
Is Target-Based Drug Discovery Efficient? Discovery and “Off-Target” Mechanisms of All Drugs
Sadri, A. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01737 · Cited by 162
Optimized Chemical Proteomics Assay for Kinase Inhibitor Profiling
Médard, G., Pachl, F., Ruprecht, B., Klaeger, S., Heinzlmeir, S., Helm, D., Qiao, H., Ku, X., Wilhelm, M., Kuehne, T., et al. (2015) · Journal of Proteome Research · doi:10.1021/pr5012608 · Cited by 142
Predicting drug–target interaction using positive-unlabeled learning
Lan, W., Wang, J., Li, M., Liu, J., Li, Y., Wu, F., & Pan, Y. F. (2016) · Neurocomputing · doi:10.1016/j.neucom.2016.03.080 · Cited by 131
High-throughput imaging: Focusing in on drug discovery in 3D
Li, L., Zhou, Q., Voss, T. C., Quick, K. L., & LaBarbera, D. V. (2015) · Methods · doi:10.1016/j.ymeth.2015.11.013 · Cited by 131
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update
Wu, T., Qin, Z., Tian, Y., Wang, J., Xu, C., Li, Z., & Bian, J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00744 · Cited by 121
The utility of target-based discovery
Croston, G. E. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1308351 · Cited by 118
“Once thought to be extremely difficult to target, protein kinases are now targeted by increasing numbers of drugs, particularly in oncology [5].”
BackgroundTarget identification of natural products and bioactive compounds using affinity-based probes
Pan, S., Zhang, H., Wang, C., Yao, S. C. L., & Yao, S. Q. (2015) · Natural Product Reports · doi:10.1039/c5np00101c · Cited by 111
The Power of Sophisticated Phenotypic Screening and Modern Mechanism-of-Action Methods
Wagner, B. K., & Schreiber, S. L. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2015.11.008 · Cited by 124
“The cancer field has had more success in targeted approaches for drug discovery, perhaps due to the success of kinase inhibition (Moffat et al., 2014), but it seems likely that cancer drug discovery will ultimately witness the same trends, with phenotype-based screening and discovery playing a more…”
Cheng, K., Lee, J., Hao, P., Yao, S. Q., Ding, K., & Li, Z. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201709584 · Cited by 110
Drug discovery and development for rare genetic disorders
Sun, W., Zheng, W., & Simeonov, A. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38326 · Cited by 107
Anticancer drug discovery from Chinese medicinal herbs
Huang, M., Zhang, L., Ding, J., & Lu, J. (2018) · Chinese Medicine · doi:10.1186/s13020-018-0192-y · Cited by 117
Zheng, C., Yu, X., Liang, Y., Zhu, Y., He, Y., Liao, L., Wang, D.-K., Yang, Y., Yin, X., Li, A., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.007 · Cited by 106
Peptide-Drug Conjugates: A New Hope for Cancer Management
Chavda, V. P., Solanki, H. K., Davidson, M., Apostolopoulos, V., & Bojarska, J. (2022) · Molecules · doi:10.3390/molecules27217232 · Cited by 103
“A targeted approach uses a direct evolution technique for rationally designed peptides (combined principles of biology with materials science) for selected targets [35,36].”
Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics
de Waal, L., Lewis, T. A., Rees, M. G., Tsherniak, A., Wu, X., Choi, P. S., Gechijian, L., Hartigan, C., Faloon, P. W., Hickey, M. J., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.1984 · Cited by 96
“Many U.S. Food and Drug Administration (FDA)- approved targeted therapies have been developed using this approach, among them small-molecule kinase inhibitors that target oncogenic somatic driver mutations 2 .”
BackgroundDegradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer
Dieter, S. M., Siegl, C., Codó, P. L., Huerta, M., Ostermann-Parucha, A. L., Schulz, E., Zowada, M. K., Martin, S., Laaber, K., Nowrouzi, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109394 · Cited by 95
Lessons Learned from Two Decades of Anticancer Drugs
Liu, Z., Delavan, B., Roberts, R. A., & Tong, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.005 · Cited by 103
“Between 1999 and 2013, 21 of 31 oncology new molecule entities (NMEs) discovered by target-based approaches were kinase inhibitors [32].”
BackgroundTurning liabilities into opportunities: Off-target based drug repurposing in cancer
Palve, V. C., Liao, Y., Rix, L. L. R., & Rix, U. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.003 · Cited by 103
Karawajczyk, A., Giordanetto, F., Benningshof, J. C. J., Hamza, D., Kalliokoski, T., Pouwer, K., Morgentin, R., Nelson, A. S., Müller, G., Piechot, A., et al. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.009 · Cited by 105
Next-Generation Phenotypic Screening in Early Drug Discovery for Infectious Diseases
Aulner, N., Danckaert, A., Ihm, J., Shum, D., & Shorte, S. L. (2019) · Trends in Parasitology · doi:10.1016/j.pt.2019.05.004 · Cited by 96
“Not least, the emergence of promising new improved phenotypic methods, which are based on enhanced biological relevance [17, 18], has led some to claim that phenotypic screens surpass target-based approaches in identification of first-in-class scaffolds [14,16].”
BackgroundSpatial light interference microscopy: principle and applications to biomedicine
Chen, X., Kandel, M. E., & Popescu, G. (2021) · Advances in Optics and Photonics · doi:10.1364/aop.417837 · Cited by 95
EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen
Scheipl, S., Barnard, M., Cottone, L., Jørgensen, M., Drewry, D. H., Zuercher, W. J., Turlais, F., Ye, H., Leite, A. P., Smith, J. A., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4729 · Cited by 96
Plant Chemical Genetics: From Phenotype-Based Screens to Synthetic Biology
Dejonghe, W., & Russinova, E. (2017) · PLANT PHYSIOLOGY · doi:10.1104/pp.16.01805 · Cited by 90
“Similarly, examples from the 529 mammalian drug discovery field, in which small-molecule hits have been found to 530 additionally affect mitochondrial function (Moffat et al., 2014; Wallace, 2015), emphasize the 531 need for a thorough analysis of off-target effects.”
BackgroundInfluentialWhy and how have drug discovery strategies in pharma changed? What are the new mindsets?
Mignani, S. M., Huber, S., Tomás, H., Rodrigues, J., & Majoral, J. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.007 · Cited by 85
Kang, J., Hsu, C.-H., Wu, Q., Liu, S., Coster, A. D., Posner, B. A., Altschuler, S. J., & Wu, L. F. (2015) · Nature Biotechnology · doi:10.1038/nbt.3419 · Cited by 89
Morphological profiling of small molecules
Ziegler, S., Sievers, S., & Waldmann, H. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.02.012 · Cited by 98
Use of artificial intelligence to enhance phenotypic drug discovery
Malandraki-Miller, S., & Riley, P. R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.013 · Cited by 97
Rodenhizer, D., Dean, T., D'Arcangelo, E., & McGuigan, A. P. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701174 · Cited by 80
Entrectinib, a new multi-target inhibitor for cancer therapy
Jiang, Q., Li, M., Li, H., & Chen, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112974 · Cited by 86
Li, B., Xia, A., Xie, S., Lin, L., Ji, Z., Suo, T., Zhang, X., & Huang, H. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.0c05275 · Cited by 79
The role and application of bioinformatics techniques and tools in drug discovery
Zhang, S., Liu, K., Liu, Y., Hu, X., & Gu, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1547131 · Cited by 110
Coussens, N. P., Braisted, J. C., Peryea, T., Sittampalam, G. S., Simeonov, A. M., & Hall, M. D. (2017) · Pharmacological Reviews · doi:10.1124/pr.117.013755 · Cited by 81
“The alternative target-based screening route is to engineer a cell-based assay that informs directly on target engagement or modulation (Moffat et al., 2014).”
BackgroundTarget deconvolution from phenotype-based drug discovery by using chemical proteomics approaches
Kubota, K., Funabashi, M., & Ogura, Y. (2018) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2018.08.002 · Cited by 88
Recent Applications of Diazirines in Chemical Proteomics
Halloran, M. W., & Lumb, J. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201805004 · Cited by 84
Wu, S., Li, Y., Xu, G., Chen, S., Zhang, Y., Liu, N., Dong, G., Miao, C., Su, H., Zhang, W., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.039 · Cited by 74
Recent advances in phenotypic drug discovery
Swinney, D. C., & Lee, J. A. (2020) · F1000Research · doi:10.12688/f1000research.25813.1 · Cited by 80
Allred, T. K., Manoni, F., & Harran, P. G. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00126 · Cited by 73
Shrimp, J. H., Sorum, A. W., Garlick, J. M., Guasch, L., Nicklaus, M. C., & Meier, J. L. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00385 · Cited by 74
Accurate Morphology Preserving Segmentation of Overlapping Cells based on Active Contours
Molnár, C., Jermyn, I. H., Kató, Z., Rahkama, V., Östling, P., Mikkonen, P., Pietiäinen, V., & Horváth, P. (2016) · Scientific Reports · doi:10.1038/srep32412 · Cited by 71
“γ λ γ α γ = + E L A ( ) ( ) ( ), (1) AC C C”
Pun, N. T., & Jeong, C. (2021) · Pharmaceuticals · doi:10.3390/ph14050470 · Cited by 75
How Phenotypic Screening Influenced Drug Discovery: Lessons from Five Years of Practice
Haasen, D., Schopfer, U., Antczak, C., Guy, C. T., Fuchs, F., & Selzer, P. M. (2017) · Assay and Drug Development Technologies · doi:10.1089/adt.2017.796 · Cited by 75
“Like others, 3,13 we wanted to assess our efforts in phenotypic drug discovery and analyzed past and ongoing phenotypic screens for potential success factors.”
Yang, Y., Cao, L., Gao, H., Wu, Y., Wang, Y., Fang, F., Lan, T., Lou, Z., & Rao, Y. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00091 · Cited by 72
López‐Lázaro, M. (2015) · Oncoscience · doi:10.18632/oncoscience.132 · Cited by 69
“Despite the recent approval of numerous anticancer drugs [1], most of these patients do not overcome the disease.”
BackgroundPhenotypic Identification of a Novel Autophagy Inhibitor Chemotype Targeting Lipid Kinase VPS34
Robke, L., Laraia, L., Corrales, M. A. C., Konstantinidis, G., Muroi, M., Richters, A., Winzker, M., Engbring, T., Tomassi, S., Watanabe, N., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201703738 · Cited by 68
Grafton, F., Ho, J. J., Ranjbarvaziri, S., Farshidfar, F., Budan, A., Steltzer, S. S., Maddah, M., Loewke, K. E., Green, K., Patel, S. D., et al. (2021) · eLife · doi:10.7554/elife.68714 · Cited by 74
Recent Advances and Perspectives in Cancer Drug Design
Magalhães, L. G., Ferreira, L. L. G., & Andricopulo, A. D. (2018) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201820170823 · Cited by 80
Comess, K. M., McLoughlin, S. M., Oyer, J. A., Richardson, P. L., Stöckmann, H., Vasudevan, A., & Warder, S. E. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01921 · Cited by 71
The development of high-content screening (HCS) technology and its importance to drug discovery
Fraietta, I., & Gasparri, F. (2016) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1165203 · Cited by 76
Cheminformatics Tools for Analyzing and Designing Optimized Small Molecule Collections and Libraries
Moret, N., Clark, N. A., Hafner, M. A., Wang, Y., Lounkine, E., Medvedovic, M., Wang, J., Gray, N. S., Jenkins, J. L., & Sorger, P. K. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2019.02.018 · Cited by 67
“Careful screening of focused libraries has resulted in the identification of “first-in-class” drugs (Eder et al., 2014; Moffat et al., 2014; Swinney and Anthony, 2011) such as Vorinostat (Marks, 2007) and Miglustat (Ficicioglu, 2008) and led to repurposing of (investigational) drugs such as…”
BackgroundRiggs, J. R., Nagy, M. A., Elsner, J., Erdman, P. E., Cashion, D., Robinson, D., Harris, R., Huang, D., Tehrani, L. R., Deyanat‐Yazdi, G., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01223 · Cited by 65
Semenova, M. N., Demchuk, D. V., Tsyganov, D. V., Чернышева, Н. Б., Samet, A. V., Silyanova, E. A., Кислый, В. П., Maksimenko, A. S., Varakutin, A. E., Konyushkin, L. D., et al. (2018) · ACS Combinatorial Science · doi:10.1021/acscombsci.8b00113 · Cited by 65
Pavlinov, I., Salkovski, M., & Aldrich, L. N. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b12705 · Cited by 65
Cheeseman, M. D., Chessum, N. E. A., Rye, C. S., Pasqua, E., Tucker, M. J., Wilding, B., Evans, L. E., Lepri, S., Richards, M., Sharp, S. Y., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01055 · Cited by 64
High-content phenotypic and pathway profiling to advance drug discovery in diseases of unmet need
Hughes, R. E., Elliott, R. J. R., Dawson, J. C., & Carragher, N. O. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.02.015 · Cited by 62
Flow Cytometry: Impact on Early Drug Discovery
Edwards, B. S., & Sklar, L. A. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115578273 · Cited by 66
Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells
Corominas-Faja, B., Cuyàs, E., Lozano‐Sánchez, J., Cufí, S., Verdura, S., Fernández‐Arroyo, S., Borrás‐Linares, I., Martín-Castillo, B., Martín, Á. G., Lupu, R., et al. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy023 · Cited by 67
“In contrast to the target-based strategies that have been widely employed in the pharmaceutical cancer industry in the past decades, including those aimed to discover new anti-CSC drugs, we chose to uncover novel EVOO-derived anti-CSC biophenols by employing a cell-based phenotypic drug discovery strategy coupled to m…”
MethodPatient-Derived Tumor Xenograft Models: Toward the Establishment of Precision Cancer Medicine
Goto, T. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030064 · Cited by 69
“These drugs have been analyzed using models involving the constant proliferation of tumor cells [14].”
BackgroundSun, W., Luan, S., Qi, C., Tong, Q., Yan, S., Li, H., & Zhang, Y. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0425-4 · Cited by 61
Surovtseva, Y. V., Jairam, V., Salem, A. F., Sundaram, R. K., Bindra, R. S., & Herzon, S. B. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b00162 · Cited by 66
pdCSM-cancer: Using Graph-Based Signatures to Identify Small Molecules with Anticancer Properties
Al‐Jarf, R., de Sá, A. G. C., Pires, D. E. V., & Ascher, D. B. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00168 · Cited by 65
Computer vision for high content screening
Kraus, O. Z., & Frey, B. J. (2016) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1135868 · Cited by 63
“In pharmaceutical research, primary high content screening of drug candidates using in vitro cell assays has enabled more informed drug discovery (Lang et al ., 2006; Moffat et al ., 2014).”
BackgroundEvidence-Based and Quantitative Prioritization of Tool Compounds in Phenotypic Drug Discovery
Wang, Y., Cornett, A., King, F., Mao, Y., Nigsch, F., PARIS, C. G., McAllister, G., & Jenkins, J. L. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.05.016 · Cited by 57
Anastasov, N., Höfig, I., Radulović, V., Ströbel, S., Salomon, M., Lichtenberg, J., Rothenaigner, I., Hadian, K., Kelm, J. M., Thirion, C., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1481-9 · Cited by 56
“The hanging drop system, the oldest cell culture technique of all, has undergone a recent rebirth [12, 29] showing great potential for making cancer screening assays more predictive and informative [5].”
BackgroundAnticancer metallohelices: nanomolar potency and high selectivity
Kaner, R. A., Allison, S. J., Faulkner, A. D., Phillips, R. M., Roper, D. I., Shepherd, S. L., Simpson, D. H., Waterfield, N. R., & Scott, P. (2015) · Chemical Science · doi:10.1039/c5sc03677a · Cited by 55
Sawada, R., Iwata, M., Tabei, Y., Yamato, H., & Yamanishi, Y. (2018) · Scientific Reports · doi:10.1038/s41598-017-18315-9 · Cited by 58
Chen, S., Dong, G., Wu, S., Liu, N., Zhang, W., & Sheng, C. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.08.003 · Cited by 54
Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer
Gao, M., Lin, M., Moffitt, R. A., Salazar, M. D., Park, J. M., Vacirca, J. L., Huang, C., Shroyer, K. R., Choi, M., Georgakis, G. V., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0298-0 · Cited by 55
Schneidewind, T., Kapoor, S., Garivet, G., Karageorgis, G., Narayan, R., Vendrell‐Navarro, G., Antonchick, A. P., Ziegler, S., & Waldmann, H. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2018.11.014 · Cited by 54
Metadata
- Authors
- Moffat, J. G., Rudolph, J., & Bailey, D.
- Affiliations
- Genentech (US)
- Corresponding author
- Moffat, John G.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-07-18
- Volume
- 13
- Issue
- 8
- Pages
- 588-602
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2123059506
- Semantic Scholar
- 1042a4c884176fac046b7c6751c953ed949f8066
- Cited by
- 507
- References
- 182
- Citations by year
- 2026: 28 · 2025: 37 · 2024: 43 · 2023: 30 · 2022: 36 · 2021: 48 · 2020: 45 · 2019: 48 · 2018: 52 · 2017: 56 · 2016: 42 · 2015: 39 · 2014: 3
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Food and Drug Administration
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- phenotypic screening, anticancer drug discovery, anticancer drug development, small molecule anticancer agents, FDA-approved anticancer drugs, target-based drug discovery, cytotoxicity, mitotic arrest
- MeSH terms
- Antineoplastic Agents, Drug Screening Assays, Antitumor, Forecasting, Humans, Neoplasms, Phenotype, History, 20th Century, History, 21st Century, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.